Skip to main content

Table 1 Respondent characteristics

From: Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey

 

MF (n = 207)

PV (n = 380)

ET (n = 226)

Median (range) age, y

66 (28–90)

64 (25–94)

62 (23–87)

Women, n (%)

112 (54)

237 (62)

163 (72)

Race,a n (%)

   

 White

203 (98)

371 (98)

221 (98)

 Black or African American

2 (1)

3 (1)

2 (1)

 Asian

1 (<1)

4 (1)

2 (1)

 Unknown

1 (<1)

2 (1)

1 (<1)

Median (range) disease duration since diagnosis, y

4 (0–36)

7 (0–61)

7 (0–36)

Calculated prognostic risk score, n (%)

   

 Low

9 (4)

26 (7)

46 (20)

 Intermediate-1

34 (16)

77 (20)

86 (38)

 Intermediate-2

84 (41)

62 (16)

NAb

 High

63 (30)

101 (27)

35 (16)

 Missingc

17 (8)

114 (30)

59 (26)

Primary medical insurance, n (%)

   

 Medicare

94 (45)

157 (41)

84 (38)

 Group commercial insurance

80 (39)

169 (45)

103 (46)

 Individual commercial insurance

14 (7)

25 (7)

18 (8)

 Medicaid or state assistance

1 (<1)

3 (1)

1 (<1)

 Tricare or VA benefit

6 (3)

4 (1)

8 (4)

 Medicare and group insurance through current/former employer

3 (1)

3 (1)

2 (1)

 Medicare and secondary/supplemental insurance

3 (1)

2 (1)

2 (1)

 Other

5 (2)

13 (3)

5 (2)

 Unknown

1 (<1)

2 (1)

0

Education, n (%)

   

 No high school

1 (<1)

0

0

 Some high school

0

1 (<1)

1 (<1)

 High school graduate

17 (8)

33 (9)

20 (9)

 Technical postsecondary

7 (3)

11 (3)

11 (5)

 Some college

48 (23)

88 (23)

63 (28)

 Four-year college graduate

67 (32)

116 (31)

58 (26)

 Postgraduate degree

67 (32)

131 (35)

73 (32)

Household income, n (%)

   

 ≤$15,000

6 (3)

12 (3)

9 (4)

 15,001–$25,000

9 (4)

21 (6)

9 (4)

 25,001–$35,000

19 (9)

22 (6)

11 (5)

 35,001–$50,000

17 (8)

37 (10)

22 (10)

 50,001–$75,000

34 (16)

62 (16)

35 (16)

 75,001–$100,000

47 (23)

53 (14)

60 (27)

 >$100,000

62 (30)

145 (38)

67 (30)

 Unknown

13 (6)

28 (7)

13 (6)

  1. ET = essential thrombocythemia; MF = myelofibrosis; NA = not applicable; PV = polycythemia vera; VA = Veterans Affairs
  2. aRespondents were allowed to give multiple answers regarding race; this table records only the first answer given by each respondent
  3. bRespondents with ET could receive prognostic risk scores of low, intermediate, or high; intermediate was not divided into intermediate-1 and -2
  4. cCalculated prognostic risk score missing because of unknown lab values for risk categorization